Status:
COMPLETED
Identification of Immunogenic Neo-epitopes for the Development of Personalised Pancreatic Cancer Vaccines
Lead Sponsor:
Queen Mary University of London
Conditions:
The Initial Aim of This Project is to Perform in Vitro Validation of Neoepitope Candidates Selected From Available Mutanome Data
Eligibility:
All Genders
17-70 years
Brief Summary
Human pancreatic cancer has a very poor prognosis with an overall survival rate of less than 5%. Current treatment regimens are ineffective and even if the patient responds to initial treatments, rela...
Detailed Description
Background Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive tumour types, with an extremely poor prognosis. Without active treatment, patients with metastatic PDAC have a mean sur...
Eligibility Criteria
Inclusion
- fit and healthy;
- weigh over 7 stone 12 lbs or 50kg;
- are aged between 17 and 66 (or 70 if you have given blood before);
- are over 70 and have given blood in the last two years.
Exclusion
- receiving treatment;
- taking medication;
- travelling outside of the UK;
- tattoos;
- pregnancy;
- illness;
- cancer;
- received blood, blood products or organs.
Key Trial Info
Start Date :
September 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2021
Estimated Enrollment :
192 Patients enrolled
Trial Details
Trial ID
NCT04379960
Start Date
September 1 2016
End Date
October 1 2021
Last Update
September 22 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Barts Cancer Institute
London, United Kingdom, EC1M 6BQ